Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.

NCT02565628 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02565628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02565628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2015
Completion date
May 13, 2016
Enrollment
20 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson's disease